• Citer

A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.

par Heath, Elisabeth I;Lorusso, Patricia;Ramalingam, Suresh S;Awada, Ahmad ;Egorin, Merrill J;Besse-Hammer, Tatiana;Cardoso, Fatima ;Valdivieso, Manuel;Has, Teresa;Alland, Leila;Zhou, Xiaofei;Belani, Chandra Prakash
Référence Investigational new drugs, 29, 6, page (1426-1431)
Publication Publié, 2011-12

Article révisé par les pairs

• Détails
• Contenu

Titre:	A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
Auteur:	Heath, Elisabeth I; Lorusso, Patricia; Ramalingam, Suresh S; Awada, Ahmad; Egorin, Merrill J; Besse-Hammer, Tatiana; Cardoso, Fatima; Valdivieso, Manuel; Has, Teresa; Alland, Leila; Zhou, Xiaofei; Belani, Chandra Prakash
Informations sur la publication:	Investigational new drugs, 29, 6, page (1426-1431)
Statut de publication:	Publié, 2011-12
Sujet CREF:	Cancérologie
Mots-clés:	Oral
	Paclitaxel
	Phase I
MeSH keywords:	Administration, Oral
	Aged
	Antineoplastic Agents -- administration & dosage -- adverse effects -- pharmacokinetics
	Bridged Compounds -- administration & dosage -- adverse effects -- pharmacokinetics
	Dose-Response Relationship, Drug
	Drug Administration Schedule
	Female
	Humans
	Male
	Middle Aged
	Neoplasms -- drug therapy -- pathology
	Neutropenia -- chemically induced
	Sepsis -- chemically induced
	Treatment Outcome
Note générale:	Clinical Trial, Phase I
	Journal Article
	Multicenter Study
	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0167-6997
	info:doi/10.1007/s10637-010-9498-z
	info:scp/84856051059
	info:pmid/20680660